The efficacy of preoperative administration of a single dose of recombinant human erythropoietin in pediatric cardiac surgery

Heart Surgery Forum

Volumn 10, Issue 2, 2007, Pages 86-90

  Ootaki, Yosfaio ^a,b   Yamaguchi, Masahiro ^a   Yoshimura, Naoki ^a   Oka, Shigeteru ^a   Yoshida, Masahiro ^a   Hasegawa, Tomomi ^a  

^a KOBE CHILDREN S HOSPITAL   (Japan)

^b NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS SULFATE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLEEDING; CONTROLLED STUDY; CYANOTIC HEART DISEASE; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE DRUG DOSE; BLOOD ANALYSIS; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONGENITAL HEART MALFORMATION; CYANOSIS; DOSE RESPONSE; FOLLOW UP; METHODOLOGY; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROBABILITY; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

BLOOD CHEMICAL ANALYSIS; CARDIAC SURGICAL PROCEDURES; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; CYANOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HEART DEFECTS, CONGENITAL; HEMATOCRIT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PROBABILITY; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34247479068     PISSN: 10983511     EISSN: None     Source Type: Journal    
DOI: 10.1532/HSF98.20061183     Document Type: Article

References (25)

1. Bennett CL, Luminari S, Nissenson AR, et al. 2004. Pure red-cell aplasia and epoetin therapy. N Engl J Med 351:1403-8.
2. Bidstrup BP, Royston D, Sapsford RN, et al. 1989. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97:364-72.
3. Cook DJ, Orszulak TA, Daly RC, et al. 1997. Minimum hematocrit for normothermic cardiopulmonary bypass in dogs. Circulation 96:11200-4.
4. Coyle D, Lee KM, Fergusson DA, et al. 2000. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics 18:161-71.
5. D'Ambra MN, Gray RJ, Hillman R, et al. 1997. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 64:1686-93.
6. De Andrade JR, Jove M, Landon G, et al. 1996. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop 25:533-42.
7. Engoren MC, Habib RH, Zacharias A, et al. 2002. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 74:1180-6.
8. Fukahara K, Murakami A, Ueda T, et al. 1997. Scheduled autologous blood donation at the time of cardiac catheterization in infants and children. J Thorac Cardiovasc Surg 114:504-5.
9. Haga P, Cotes PM, Till JA, et al. 1987. Serum immunoreactive erythropoietin in children with cyanotic and acyanotic congenital heart disease. Blood 70:822-6.
10. Hardy JF, Belisle S, Janvier G, et al. 1996. Reduction in requirements for allogeneic blood products: nonpharmacologic methods. Ann Thorac Surg 62:1935-43.
11. Jacobs K, Shoemaker C, Rudersdorf R, et al. 1985. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313:806-10.
12. Kiyama H, Ohshima N, Imazeki T, et al. 1999. Autologous blood donation with recombinant human erythropoietin in anemic patients. AnnThorac Surg 68:1652-6.
13. Kuehnert MJ, Roth VR, Haley NR, et al. 2001. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 41:1493-9.
14. Kurth CD, Steven JM, Nicolson SC, et al. 1997. Cerebral oxygenation during cardiopulmonary bypass in children. J Thorac Cardiovasc Surg 113:71-9.
15. Masuda M, Kawachi Y, Inaba S, et al. 1995. Preoperative autologous blood donations in pediatric cardiac surgery. Ann Thorac Surg 60:1694-7.
16. Michalopoulos A, Tzelepis G, Dafni U, et al. 1999. Determinants of hospital mortality after coronary artery bypass grafting. Chest 115:1598-603.
17. Miyake T, Kung CK, Goldwasser E. 1977. Purification of human erythropoietin. J Biol Chem 252:5558-64.
18. Ootaki Y, Yamaguchi M, Oshima Y, et al. 2002. Effects of modified ultrafiltration on coagulation factors in pediatric cardiac surgery. Surg Today 32:203-6.
19. Ootaki Y, Yamaguchi M, Yoshimura N, et al. 2004. Efficacy of a criterion driven transfusion protocol in pediatric cardiac surgery patients. J Thorac Cardiovasc Surg 127:953-8.
20. Shimpo H, Mizumoto T, Onoda K, et al. 1997. Erythropoietin in pediatric cardiac surgery: clinical efficacy and effective dose. Chest 111:1565-70.
21. Sowade O, Warnke H, Scigalla P, et al. 1997. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. Blood 89:411-8.
22. Strauss RG. 1994. Can the cost of erythropoietin for cardiac surgery patients be justified? Transfusion 34:835.
23. Tyndall MR, Teitel DF, Lutin WA, et al. 1987. Serum erythropoietin levels in patients with congenital heart disease. J Pediatr 110:538-44.
24. Watanabe Y, Fuse K, Konishi T, et al. 1991. Autologous blood transfusion with recombinant human erythropoietin in heart operations. Ann Thorac Surg 51:767-72.
25. Yazicioglu L, Eryilmaz S, Sirlak M, et al. 2001. Recombinant human erythropoietin administration in cardiac surgery. J Thorac Cardiovasc Surg 122:741-5.